oxidation of benzyl group to ketones at ambient conditions, while usingwater as the sole oxygensource. Water addition reduces the onset potential of anodic C–H oxidation, and produces 1-tetralone with satisfying conversion and excellent ketone to alcohol ratio. Layered MnO2 catalysts (with rich oxygen vacancies) further adjust the water affinity and facilitate the oxidation, leading to a significantly
3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS
申请人:Forma Therapeutics, Inc.
公开号:US20160304456A1
公开(公告)日:2016-10-20
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6 and HDAC11, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.